Valeant Pharma (VRX) Receives FDA CRL on Eye Drops Related to Manufacturing Deficiencies; No NDA Efficacy, Safety Concerns Noted
Tweet Send to a Friend
Early Friday, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced it has received a Complete Response Letter (CRL) from the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE